The first reported clinical use of perinatal-derived tissue allografts for aiding in wound healing was at Johns Hopkins over a century ago in 1910. In recent years, both clinical and research applications of these biomaterials have increased in scope to include roles in tissue engineering and regenerative medicine. Perinatal tissues are an abundant source of extracellular matrix components and growth factors, with potential use in a broad array of regenerative therapies. These components have translated well to regenerative applications owing to their low immunogenicity, positive wound healing characteristics, and minimal tissue inflammation1-2. The two most widely adopted perinatal components for clinical use are the umbilical cord and the amniotic membrane.